Reversible AChE inhibitors are prescribed for medical conditions of reduced acetylcholine function including myasthenia gravis and Alzheimer’s disease (Nair and Hunter, 2004). Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.